At the EHA, MolecularMD and OncoMed will present the validation studies for the proprietary Notch1 NGS assay being developed to identify Notch1 mutation status in patients with certain hematologic malignancies.
Notch1 mutations have been linked to more refractory lymphoid malignancies, such as chronic lymphocytic leukemia, mantle cell lymphoma, and others, putting patients at greater risk for poor outcomes and reduced overall survival.
The MolecularMD Notch1 NGS Assay is being developed as a companion diagnostic to identify patients whose cancer may be more likely to benefit from treatment with OncoMed’s anti-Notch1 antibody, OMP-52M51, currently in Phase I clinical studies.
